Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $2.3 million.

  • Assembly Biosciences' Change in Accured Expenses rose 97.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 478.87%. This contributed to the annual value of $1.4 million for FY2024, which is 162.05% up from last year.
  • Latest data reveals that Assembly Biosciences reported Change in Accured Expenses of $2.3 million as of Q3 2025, which was up 110.05% from $1.1 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Change in Accured Expenses high stood at $2.4 million for Q4 2024, and its period low was -$8.3 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.1 million (2025), whereas its average is -$180,273.
  • As far as peak fluctuations go, Assembly Biosciences' Change in Accured Expenses tumbled by 131.79% in 2023, and later soared by 490.07% in 2024.
  • Over the past 5 years, Assembly Biosciences' Change in Accured Expenses (Quarterly) stood at $1.4 million in 2021, then climbed by 15.49% to $1.6 million in 2022, then fell by 27.32% to $1.2 million in 2023, then soared by 98.57% to $2.4 million in 2024, then skyrocketed by 97.03% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $1.1 million for Q2 2025, and -$4.6 million during Q1 2025.